Detail akcie Astra Zeneca Depository Receipt online

Business Summary: AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
Financial Summary: BRIEF: For the six months ended 30 June 2025, AstraZeneca PLC (ADR) revenues increased 9% to $28.05B. Net income increased 31% to $5.37B. Revenues reflect Farxiga segment increase from $1.94B to $4.21B, Tagrisso segment increase from $1.61B to $3.49B, United States segment increase from $5.57B to $11.97B, Europe segment increase from $2.73B to $5.83B. Net income benefited from Fair Value Adjustments on Other Asse decrease of 69% to $78M (expense).